{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:44Z","timestamp":1761894704609},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1157\/13115006","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T21:51:18Z","timestamp":1208901078000},"page":"33-45","source":"Crossref","is-referenced-by-count":10,"title":["Gu\u00eda de prevenci\u00f3n y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Espa\u00f1ola de Medicina Interna"],"prefix":"10.1016","volume":"208","author":[{"given":"M.","family":"Sosa Henr\u00edquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"D\u00edaz Curiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"D\u00edez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"G\u00f3mez Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gonz\u00e1lez Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Farrerons Minguella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Filgueira Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mellibovsky Saidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Nogu\u00e9s Sol\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hern\u00e1ndez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13115006_bb0005","first-page":"137","article-title":"The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism)","volume":"1","author":"Cushing","year":"1932","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1157\/13115006_bb0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/8756-3282(94)90280-1","article-title":"Epidemiology and clinical features of osteoporosis in young individuals","volume":"15","author":"Khosla","year":"1994","journal-title":"Bone"},{"key":"10.1157\/13115006_bb0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.313.7053.344","article-title":"Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study","volume":"313","author":"Walsh","year":"1996","journal-title":"Br Med J"},{"key":"10.1157\/13115006_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.61.1.32","article-title":"Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice","volume":"61","author":"Gudbjornsson","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0025","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","article-title":"Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol,and calcitonin","volume":"328","author":"Sambrook","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1157\/13115006_bb0030","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/jbmr.5650051204","article-title":"Corticosteroid effects on proximal femur bone loss","volume":"5","author":"Sambrook","year":"1990","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00298431","article-title":"Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study","volume":"57","author":"Saito","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0040","series-title":"Coordinador. Protocolos. Osteoporosis. Sociedad Espa\u00f1ola de Medicina Interna (SEMI)","first-page":"11","article-title":"La osteoporosis: una enfermedad de los internistas","author":"Sosa Henr\u00edquez","year":"2004"},{"key":"10.1157\/13115006_bb0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1157\/13078245","article-title":"La osteoporosis. Una enfermedad de los internistas","volume":"205","author":"Sosa Henr\u00edquez","year":"2005","journal-title":"Rev Clin Esp"},{"key":"10.1157\/13115006_bb0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1157\/13078249","article-title":"\u00bfQu\u00e9 opinan los internistas espa\u00f1oles de la osteoporosis?","volume":"205","author":"Sosa Henr\u00edquez","year":"2005","journal-title":"Rev Clin Esp"},{"key":"10.1157\/13115006_bb0055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0014-2565(03)71338-1","article-title":"Osteoporosis postmenop\u00e1usica. Gu\u00eda de pr\u00e1ctica cl\u00ednica","volume":"203","year":"2003","journal-title":"Rev Clin Esp"},{"key":"10.1157\/13115006_bb0060","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-based medicine. A new approach to teaching the practice of medicine","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"10.1157\/13115006_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what is it and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"10.1157\/13115006_bb0070","first-page":"377","article-title":"La medicina basada en la evidencia: un intento de acercar la ciencia al arte de la pr\u00e1ctica cl\u00ednica","volume":"107","author":"Guerra Romero","year":"1996","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13115006_bb0075","first-page":"740","article-title":"Evaluaci\u00f3n de la evidencia cient\u00edfica","volume":"105","author":"Jovell","year":"1995","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13115006_bb0080","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.1995.03530220066035","article-title":"Users\u2019 Guides to the Medical Literature: IX. A method for grading health care recommendations","volume":"274","author":"Guyatt","year":"1995","journal-title":"JAMA"},{"key":"10.1157\/13115006_bb0085","unstructured":"Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument.London. 2001 [consultado 6 de septiembre de 2006]. Disponible en:www.agreecollaboration.org"},{"key":"10.1157\/13115006_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2796.1998.00408.x","article-title":"A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update","volume":"244","author":"Eastell","year":"1998","journal-title":"J Intern Med"},{"key":"10.1157\/13115006_bb0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00198-005-2032-z","article-title":"Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club","volume":"17","author":"Devogelaer","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0100","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2005.03.006","article-title":"Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science","volume":"35","author":"Abadie","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1157\/13115006_bb0110","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1210\/jcem.86.12.8066","article-title":"Glucocorticoid-Induced Osteoporosis: Summary of a Workshop","volume":"86","author":"Canalis","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s003930170081","article-title":"Preliminary consensus statement on glucocorticoid-induced osteoporosis","volume":"60","author":"Scharla","year":"2001","journal-title":"Z Rheumatol"},{"key":"10.1157\/13115006_bb0120","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1001\/archinte.163.21.2619","article-title":"Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs","volume":"163","author":"Adler","year":"2003","journal-title":"Arch Inter Med"},{"key":"10.1157\/13115006_bb0125","series-title":"Controversias en Osteoporosis","first-page":"9","article-title":"Osteoporosis inducida por corticoids","author":"J\u00f3dar Gimeno","year":"2006"},{"key":"10.1157\/13115006_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard.54.1.49","article-title":"Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture","volume":"54","author":"Cooper","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0135","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"Van Staa","year":"2000","journal-title":"Rheumatology"},{"key":"10.1157\/13115006_bb0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid- induced osteoporosis: a meta-analysis","volume":"13","author":"Van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780280402","article-title":"Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases","volume":"28","author":"Dykman","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0150","unstructured":"Petrone E, Goldman R, Calis K, Chrousos GP, Cizza G. Glucocorticoid-induced osteoporosis. Basic mechanisms and clinical implications. En: Arnold A, editor. South Dartmouth, Massachusetts: Endotext. MDText.com, Inc; 2006. Disponible en: www.endotext.com"},{"key":"10.1157\/13115006_bb0155","first-page":"144","article-title":"A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo","volume":"83","author":"Huizenga","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S8756-3282(00)00344-6","article-title":"Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone","volume":"27","author":"Cooper","year":"2000","journal-title":"Bone"},{"key":"10.1157\/13115006_bb0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.186.2.189","article-title":"Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone\/cortisol shuttle","volume":"186","author":"Escher","year":"1997","journal-title":"J Exp Med"},{"key":"10.1157\/13115006_bb0170","first-page":"124","article-title":"Nelson\u2019s syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene","volume":"81","author":"Karl","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0175","first-page":"1","article-title":"Efectos de los corticosteroides inhalados sobre el metabolismo \u00f3seo en el asma y la enfermedad pulmonar obstructiva cr\u00f3nica moderada","volume":"4","author":"Jones","year":"2005","journal-title":"Biblioteca Cochrane Plus"},{"key":"10.1157\/13115006_bb0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.200305-640OC","article-title":"Inhaled and nasal corticosteroid risk of fracture","volume":"169","author":"Suissa","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13115006_bb0185","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1164\/rccm.200206-606OC","article-title":"Inhaled corticosteroids and hip fracture. A population-based case\u2013control study","volume":"166","author":"Hubbard","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13115006_bb0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jocd.2005.11.005","article-title":"Inhaled steroids do not decrease bone but increase risk of fractures: Data GIUMO Study Group","volume":"9","author":"Sosa","year":"2006","journal-title":"J Clin Densitom"},{"key":"10.1157\/13115006_bb0195","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(00)02138-3","article-title":"Inhaled corticosteroid use and bone-mineral density in patients with asthma","volume":"355","author":"Wong","year":"2000","journal-title":"Lancet"},{"key":"10.1157\/13115006_bb0200","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1378\/chest.120.5.1468","article-title":"Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients. A 4-year longitudinal study","volume":"120","author":"Matsumoto","year":"2001","journal-title":"Chest"},{"key":"10.1157\/13115006_bb0205","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1164\/ajrccm.159.3.9802096","article-title":"Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?","volume":"159","author":"Boulet","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13115006_bb0210","first-page":"93","article-title":"Prednisone- induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women","volume":"5","author":"Rizzato","year":"1988","journal-title":"Sarcoidosis"},{"key":"10.1157\/13115006_bb0215","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/03009749609065648","article-title":"Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment","volume":"25","author":"Hansen","year":"1996","journal-title":"Scand J Rheumatol"},{"key":"10.1157\/13115006_bb0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0221-8747(79)90024-9","article-title":"Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis","volume":"1","author":"Bressot","year":"1979","journal-title":"Metab Bone Dis Rel Res"},{"key":"10.1157\/13115006_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02032284","article-title":"Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment","volume":"4","author":"Lund","year":"1985","journal-title":"Clin Rheum"},{"key":"10.1157\/13115006_bb0230","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF02405069","article-title":"Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis","volume":"35","author":"Dempster","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0235","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis ofosteoblasts and osteocytes by glucocorticoids potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1157\/13115006_bb0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0022-4731(81)90270-3","article-title":"Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism in man","volume":"15","author":"Caniggia","year":"1981","journal-title":"J Steroid Biochem"},{"key":"10.1157\/13115006_bb0245","first-page":"407","article-title":"Acute changes in urinary radiocalcium following glucocorticoid administration in man","volume":"171","author":"Gennari","year":"1984","journal-title":"Adv Exp Med Biol"},{"key":"10.1157\/13115006_bb0250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/thx.46.3.160","article-title":"Bone turnover during high dose inhaled corticosteroid treatment","volume":"46","author":"Ali","year":"1991","journal-title":"Thorax"},{"key":"10.1157\/13115006_bb0255","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1210\/jcem-72-3-530","article-title":"Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin","volume":"72","author":"Hodsman","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0260","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002239900352","article-title":"Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients","volume":"61","author":"Gonnelli","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0265","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem-72-2-382","article-title":"The course of biochemical parameters of bone turnover during treatment with corticosteroids","volume":"72","author":"Prummel","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"LoCascio","year":"1990","journal-title":"Bone Miner"},{"key":"10.1157\/13115006_bb0275","first-page":"105","article-title":"The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamin acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects","volume":"4","author":"Nielsen","year":"1988","journal-title":"Bone Miner"},{"key":"10.1157\/13115006_bb0280","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/ard.54.1.66","article-title":"Steroid induced osteoporosis:an opportunity for prevention?","volume":"54","author":"Peat","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF02561402","article-title":"Steroid osteoporosis","volume":"45","author":"Reid","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0290","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1157\/13115006_bb0295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-40-1-152","article-title":"Effect of glucocorticoids on function of the parathyroid glands in man","volume":"40","author":"Fucik","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0300","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1210\/jc.2002-012101","article-title":"The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence?","volume":"87","author":"Rubin","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0305","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2362.1990.tb01875.x","article-title":"Dexamethasone increases preproparathyroid hormone messenger RNA in human hyperplastic parathyroid cells in vitro","volume":"20","author":"Peraldi","year":"1990","journal-title":"Eur J Clin Invest"},{"key":"10.1157\/13115006_bb0310","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-104-5-648","article-title":"Reduction of serum testosterone levels during chronic glucocorticoid therapy","volume":"104","author":"MacAdams","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1157\/13115006_bb0315","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bmj.291.6495.574","article-title":"Plasma testosterone concentrations in asthmatic men treated with glucocorticoids","volume":"291","author":"Reid","year":"1985","journal-title":"Br Med J"},{"key":"10.1157\/13115006_bb0320","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thx.45.8.573","article-title":"Corticosteroids and osteoporosis","volume":"45","author":"Smith","year":"1990","journal-title":"Thorax"},{"key":"10.1157\/13115006_bb0325","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/014107687807101006","article-title":"Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women","volume":"71","author":"Crilly","year":"1978","journal-title":"J R Soc Med"},{"key":"10.1157\/13115006_bb0330","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1677\/joe.0.0730235","article-title":"Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment","volume":"73","author":"Borkowski","year":"1977","journal-title":"J Endocrinol"},{"key":"10.1157\/13115006_bb0335","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1157\/13115006_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1385\/JCD:5:2:117","article-title":"Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk","volume":"5","author":"Leslie","year":"2002","journal-title":"J Clin Densitom"},{"key":"10.1157\/13115006_bb0345","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","article-title":"1999 Bone densitometry: the best way to detect osteoporosis and to monitor therapy","volume":"84","author":"Miller","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0350","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech","volume":"843","year":"1994","journal-title":"Rep Ser"},{"key":"10.1157\/13115006_bb0355","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/thx.46.11.803","article-title":"Vertebral fractures in steroid dependent asthma and involutional osteoporosis:a comparative study","volume":"46","author":"Luengo","year":"1991","journal-title":"Thorax"},{"key":"10.1157\/13115006_bb0360","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/ard.54.10.801","article-title":"Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis","volume":"54","author":"Peel","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0365","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"11","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0370","unstructured":"CB Bone and Tooth Society of Great Britain, Royal College of Physicians, National Osteoporosis Society. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis London: Royal College of Physicians; 2003."},{"key":"10.1157\/13115006_bb0375","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/ard.2003.018556","article-title":"How to prevent steroid induced osteoporosis","volume":"64","author":"Sambrook","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0380","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0248-8663(03)00105-X","article-title":"Steroid induced osteoporosis: prevention and treatment","volume":"24","author":"Roux","year":"2003","journal-title":"Rev Med Interne"},{"key":"10.1157\/13115006_bb0385","unstructured":"Glucocorticoid-induced osteoporosis. A concise guide to prevention and treatment [monograf\u00eda en Internet]. London, United Kingdom: Royal College of Physicians. Bone and Tooth Society of Great Britain; 2002."},{"key":"10.1157\/13115006_bb0390","unstructured":"University of Michigan Health System (UMHS). Osteoporosis: Prevention and treatment. Guidelines for clinical care [monograf\u00eda en Internet].Ann Arbor, MI: University of Michigan; 2002."},{"key":"10.1157\/13115006_bb0395","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00198-004-1741-z","article-title":"Bone ultrasonography in glucocorticoid-induced osteoporosis","volume":"16","author":"Cepollaro","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0400","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0301-5629(97)00195-6","article-title":"Quantitative ultrasound of the heel and serum and urinary cortisol values in assessment of long-term corticotherapy side effects in female bronchial asthma patients","volume":"23","author":"Kos-Kudla","year":"1997","journal-title":"Ultrasound Med Biol"},{"key":"10.1157\/13115006_bb0405","first-page":"305","article-title":"Contribution of calcaneal ultrasonic assessment to the evaluation of post-menopausal and glucocorticoid-induced osteoporosis","volume":"64","author":"Blanckaert","year":"1997","journal-title":"Rev Rheum"},{"key":"10.1157\/13115006_bb0410","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/j.1572-0241.1998.00685.x","article-title":"Calcaneal ultrasound bone densitometry in inflammatory bowel disease: a comparison with double X-ray densitometry of lumbar spine","volume":"93","author":"Fries","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13115006_bb0415","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s001980050227","article-title":"Efficiency of quantitative ultrasound measurements as compared with dual X-ray absorptiometry in the assessment of corticosteroid-induced bone impairment","volume":"10","author":"Daens","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0420","first-page":"1063","article-title":"Osteoporosis with low dose corticosteroids: contribution of underlying disease effects and discriminatory ability of ultrasound versus bone densitometry","volume":"28","author":"Sambrook","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1157\/13115006_bb0425","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s001980170143","article-title":"Quantitative ultrasound of bone and markers of bone turnover in Cushing\u2019s Syndrome","volume":"12","author":"Cortet","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0430","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/eje.0.1450241","article-title":"Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass","volume":"145","author":"Tauchmanova","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1157\/13115006_bb0435","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s001980170056","article-title":"Comparison of calcaneal ultrasound and DXA to assess the risk of corticosteroid induced osteoporosis: a cross-sectional study","volume":"12","author":"Javaid","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0440","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13115006_bb0445","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-years effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0450","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0455","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss. A 12-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0460","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid- induced osteoporosis in men and women: a randomized trial","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0465","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Efects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0470","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within 1 year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0475","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","article-title":"Prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate:a randomized trial","volume":"61","author":"Boutsen","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1157\/13115006_bb0480","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Boutsen","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0485","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13115006_bb0490","first-page":"2673","article-title":"Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow up","volume":"30","author":"Sato","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1157\/13115006_bb0495","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss","volume":"83","author":"Roux","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1157\/13115006_bb0500","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/ard.57.12.724","article-title":"Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study","volume":"57","author":"Geusens","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0505","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keg205","article-title":"Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis","volume":"42","author":"Ringe","year":"2003","journal-title":"Rheumatology"},{"key":"10.1157\/13115006_bb0510","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0515","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(03)00208-4","article-title":"Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray Absorptiometry and quantitative ultrasound","volume":"33","author":"Frediani","year":"2003","journal-title":"Bone"},{"key":"10.1157\/13115006_bb0520","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","article-title":"Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"11","author":"Lane","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0525","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1157\/13115006_bb0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"14","author":"Rehman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0535","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0540","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01623187","article-title":"Corticosteroid-Induced Osteoporosis: Effects of a Treatment with Slow-Release Sodium Fluoride","volume":"2","author":"Greenwald","year":"1992","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0545","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/ard.56.6.357","article-title":"Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?","volume":"56","author":"Lems","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13115006_bb0550","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jbmr.5650070909","article-title":"Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss","volume":"7","author":"Lukert","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0555","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/art.1780371014","article-title":"Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids","volume":"37","author":"Hall","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13115006_bb0560","article-title":"Calcitonin for preventing and treating corticosteroid-induced osteoporosis (Review). The Cochrane Collaboration","volume":"I","author":"Cranney","year":"2005"},{"key":"10.1157\/13115006_bb0565","unstructured":"Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcio y vitamina D para la osteoporosis inducida por corticosteroides (Revisi\u00f3n Cochrane traducida). En: La Biblioteca Cochrane Plus, 2005 N\u00famero 4. Oxford: Update Software Ltd. Disponible en: http:\/\/www.update-software.com (Traducida de The Cochrane Library, 2005 Issue 4. Chichester, UK:John Wiley & Sons, Ltd.)"},{"key":"10.1157\/13115006_bb0570","unstructured":"Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bifosfonatos para el tratamiento de la osteoporosis inducida por corticoides (Revisi\u00f3n Cochrane traducida). En: La Biblioteca Cochrane Plus, 2005 N\u00famero 4. Oxford: Update Software Ltd. Disponible en: http:\/\/www.update-software.com (Traducida de The Cochrane Library, 2005 Issue 4. Chichester, UK:John Wiley & Sons, Ltd.)"},{"key":"10.1157\/13115006_bb0575","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/jbmr.2002.17.8.1512","article-title":"The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A metaregression","volume":"17","author":"Amin","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1157\/13115006_bb0580","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis","volume":"119","author":"Laan","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1157\/13115006_bb0585","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-004-1812-1","article-title":"Evidence based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club","volume":"16","author":"Boonen","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1157\/13115006_bb0590","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0002-9343(76)90327-2","article-title":"Steroid myopathy in connective tissue disease","volume":"61","author":"Askari","year":"1976","journal-title":"Am J Med"},{"key":"10.1157\/13115006_bb0595","unstructured":"Rosen HN. Glucocorticoids and osteoporosis: Pathogenesis and clinical features. En: Rose BD, editor. Up to Date. Wellesley, MA: MDText.com, Inc.; 2006. Disponible en: http:\/\/www.endotext.com"},{"key":"10.1157\/13115006_bb0600","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256508716655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256508716655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T18:49:13Z","timestamp":1631126953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256508716655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0014256508716655"],"URL":"https:\/\/doi.org\/10.1157\/13115006","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}